Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tysabri Outreach: Unified Commitment to Health

Trial Profile

Tysabri Outreach: Unified Commitment to Health

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms TOUCH
  • Sponsors Elan Pharmaceuticals
  • Most Recent Events

    • 27 Apr 2023 Results of updated analysis (as of June 30, 2022), assessing Progressive Multifocal Leukoencephalopathy (PML) risk with natalizumab EID in comparison with Q4W dosing using TOUCH data , presented at the 75th Annual Meeting of the American Academy of Neurology 2023
    • 26 Apr 2022 Results( as of June 30, 2021) of Updated Analysis of the TOUCH Prescribing Program , presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 19 May 2020 According to a Biogen media release, data from this trial will be available online via the 2020 AAN Science Highlights virtual platform.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top